NCATS' rare disease program backs stem cell project and Lilly R&D

09/12/2013 | NIH News

The NIH's National Center for Advancing Translational Sciences will fund four research projects related to blindness and heart conditions, and the funding marks the NCATS Therapeutics for Rare and Neglected Diseases program's first collaboration with a large drugmaker as well as its first use of stem cells. A University of California, Irvine, project will explore retinitis pigmentosa treatments using retinal progenitor cells. An Eli Lilly and Co. program will focus on the treatment of hypoparathyroidism with a long-acting parathyroid hormone analog.

View Full Article in:

NIH News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC